PGLA @ 4.71 -89.17% (734 days ago) - haraldblaatand Phase III commencement 1st half CY07.
SPA approval likely by FDA in CY07.
More Phase II data on other cancer indication due Q1CY07.
Big Pharma deal likely CY07.
Share price grossly undervalued at present levels (Jan 2007).
Analyst (eGCapital) target $19.